-+ 0.00%
-+ 0.00%
-+ 0.00%
Enlivex's Phase IIb Allocetra Knee Osteoarthritis Trial Clears Interim Safety Review
Share
Listen to the news
Enlivex's Phase IIb Allocetra Knee Osteoarthritis Trial Clears Interim Safety Review
  • Enlivex reported interim safety findings supporting continued enrollment in its Phase IIb Allocetra trial for primary age-related knee osteoarthritis.
  • An independent monitoring board reviewed data from 85 randomized, dosed patients, finding the safety profile allowed enrollment to continue as planned.
  • Topline trial results will be reported in the future.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180800PRIMZONEFULLFEED9880331) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending